Results 261 to 270 of about 87,300 (320)

Newer Anticoagulants for Atrial Fibrillation: the Role of Dabigatran, Rivaroxaban, Apixaban and Edoxaban / RELY, ROCKET-AF, ARISTOTLE, & ENGAGE AF TIMI 48 Studies/ Safety Issues

, 2012
Sokratris Pastromas
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

American Heart Journal, 2018
Itamar Raz, Marc P Bonaca, Ofri Mosenzon
exaly   +2 more sources

Cancer Risk Associated with Lorcaserin - The FDA's Review of the CAMELLIA-TIMI 61 Trial.

New England Journal of Medicine, 2020
Cancer Risk Associated with Lorcaserin In early 2020, the FDA requested that the manufacturer of lorcaserin voluntarily withdraw the drug from the market because of a signal of increased cancer ris...
J. Sharretts, Ovidiu Galescu, S. Gomatam, Eugenio Andraca-Carrera, C. Hampp, L. Yanoff   +5 more
semanticscholar   +1 more source

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study

Diabetes Care, 2019
OBJECTIVE Data regarding the effects of sodium–glucose cotransporter 2 inhibitors in the elderly (age ≥65 years) and very elderly (age ≥75 years) are limited. RESEARCH DESIGN AND METHODS The Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58
A. Cahn, Ofri Mosenzon, S. Wiviott, Aliza Rozenberg, Ilan Yanuv, Erica L. Goodrich, S. Murphy, Deepak L. Bhatt, Lawrence A Leiter, D. McGuire, John P H Wilding, I. Gause-Nilsson, M. Fredriksson, P. Johansson, A. Langkilde, M. Sabatine, I. Raz   +16 more
semanticscholar   +1 more source

Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial

Thrombosis and Haemostasis, 2020
Background The effects of anticoagulants at extremes of body weight (BW) are not well described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics and clinical outcomes in patients randomized to warfarin, higher dose edoxaban ...
G. Boriani, C. Ruff, J. Kuder, M. Shi, H. Lanz, E. Antman, E. Braunwald, R. Giugliano   +7 more
semanticscholar   +1 more source

Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial.

European Heart Journal, 2019
AIMS Prior studies suggested that the risks of ischaemic stroke and bleeding in patients of Asian race with atrial fibrillation (AF) may be higher than that of non-Asians.
T. Chao, Shih‐Ann Chen, C. Ruff, Rose A. Hamershock, M. Mercuri, E. Antman, E. Braunwald, R. Giugliano   +7 more
semanticscholar   +1 more source

TIMI Risk Score predicts early readmission

International Journal of Cardiology, 2006
To assess if the TIMI Risk Score could predict early readmission.869 consecutive admissions to a Scottish district general hospital with suspected acute coronary syndrome.A computerised clinical information system was interrogated to verify readmission.
Roy L, Soiza, Niall J, Hughes, Stephen J, Leslie, Norman R, Peden, Allister D, Hargreaves   +4 more
openaire   +2 more sources

Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial

Diabetes, obesity and metabolism, 2020
To investigate whether the cardiovascular and renal benefits observed with dapagliflozin in the DECLARE‐TIMI 58 trial are also observed in patients with short and long‐standing diabetes.
H. Bajaj, I. Raz, Ofri Mosenzon, S. Murphy, Aliza Rozenberg, Ilan Yanuv, Deepak L. Bhatt, Lawrence A Leiter, D. McGuire, John P H Wilding, I. Gause-Nilsson, M. Sabatine, S. Wiviott, A. Cahn   +13 more
semanticscholar   +1 more source

Impact of preprocedural TIMI flow on clinical outcome in low‐risk patients with ST‐elevation myocardial infarction: Results from the ATLANTIC study

Catheterization and cardiovascular interventions, 2020
This study sought to analyze the impact of the preprocedural thrombolysis in myocardial infarction (TIMI) flow on clinical outcome in patients with ST‐elevation myocardial infarction (STEMI).
T. Bauer, U. Zeymer, A. Diallo, E. Vicaut, L. Bolognese, Á. Cequier, K. Huber, G. Montalescot, C. Hamm, A. V. van‘t Hof   +9 more
semanticscholar   +1 more source

The thrombolysis in myocardial infarction (TIMI) trial.

New England Journal of Medicine, 1985
W. Ganz
semanticscholar   +3 more sources